TABLE 1.
Characteristics of all patients, patients with/without recurrence and patients with/without progression*
| Parameters | Overall | Recurrence | P value | Progression | P value | ||
|---|---|---|---|---|---|---|---|
| Without | With | Without | With | ||||
| (n = 302) | (n = 105) | (n = 371) | (n = 20) | ||||
| Age (year) | 65 (59‐72) | 65 (58.8‐71.3) | 66 (59.5‐74.5) | .047a | 65 (58‐72) | 68 (62‐72.8) | .192a |
| Sex (male) | 348 (85.5) | 261 (86.4) | 87 (82.9) | .371b | 316 (85.2) | 18 (90) | .551b |
| CCI | 5 (4‐6) | 4.5 (3‐5) | 5 (4‐6) | .016a | 5 (3‐5) | 5 (5‐6) | .054a |
| Smoking status | .312b | .152c | |||||
| None | 100 (24.6) | 72 (23.8) | 28 (26.7) | 89 (24) | 7 (35) | ||
| Past smoker | 241 (59.2) | 185 (61.3) | 56 (53.3) | 223 (60.1) | 8 (40) | ||
| Active smoker | 66 (16.2) | 45 (14.9) | 21 (20) | 59 (15.9) | 5 (25) | ||
| Number of recurrences | 1 (0‐2) | 0 (0‐2) | 2 (1‐3) | <.001a | 1 (0‐2) | 2 (1‐3) | <.001a |
| Cystoscopy delay time (day) | 30 (0‐90) | 30 (0‐90) | 90 (30‐150) | <.001a | 30 (0‐90) | 91 (41‐150) | <.001a |
| Highest T stage | .041c | .052c | |||||
| PLUMP | 6 (1.5) | 6 (2) | 0 (0) | 6 (1.6) | 0 (0) | ||
| Ta | 246 (60.6) | 190 (63.1) | 56 (53.3) | 229 (61.9) | 8 (40) | ||
| T1 | 154 (37.9) | 105 (34.8) | 49 (46.6) | 135 (36.4) | 12 (60) | ||
| Highest grade | .119b | .020b | |||||
| Low | 185 (45.6) | 144 (47.8) | 41 (39) | 172 (46.5) | 4 (20) | ||
| High | 221 (54.4) | 157 (52.2) | 64 (61) | 198 (53.5) | 16 (80) | ||
| EAU risk stratification | .003b | .024b | |||||
| Low | 71 (17.4) | 64 (21.2) | 7 (6.7) | 69 (18.6) | 0 (0) | ||
| Intermediate | 103 (25.3) | 74 (24.5) | 29 (27.6) | 96 (25.9) | 3 (15) | ||
| High | 233 (57.2) | 164 (54.3) | 69 (65.7) | 206 (55.5) | 17 (85) | ||
| Intravesical therapy | .471b | .181c | |||||
| None | 142 (35) | 102 (33.9) | 40 (38.1) | 131 (35.4) | 6 (30) | ||
| Postop single‐dose MMC | 24 (5.9) | 20 (6.6) | 4 (3.8) | 24 (6.5) | 0 | ||
| MMC | 20 (4.9) | 13 (4.3) | 7 (6.7) | 17 (4.6) | 3 (15) | ||
| BCG | 220 (54.2) | 166 (55.1) | 54 (51.4) | 198 (53.5) | 11 (55) | ||
Abbreviations: BCG: Bacillus Calmette‐Guerin, CCI: Charlson Comorbidity Index, CIS: carcinoma in situ, EAU: European Association of Urology, LVI: lymphovascular invasion, MMC: mitomycin, PUNLMP: papillary urothelial neoplasm of low malignant potential, TUR: transurethral resection.
a
Mann–Whitney U‐test;
b
χ2‐test;
c
Fisher's exact test.
*
Continuous variables were given as median (25th‐75th percentile), categorical variables were given as n (%).